WO2023174523A1 - Nicotine composition - Google Patents
Nicotine composition Download PDFInfo
- Publication number
- WO2023174523A1 WO2023174523A1 PCT/EP2022/056762 EP2022056762W WO2023174523A1 WO 2023174523 A1 WO2023174523 A1 WO 2023174523A1 EP 2022056762 W EP2022056762 W EP 2022056762W WO 2023174523 A1 WO2023174523 A1 WO 2023174523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amount
- composition
- salts
- agar
- nicotine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 169
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 110
- 229960002715 nicotine Drugs 0.000 title claims abstract description 102
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920001817 Agar Polymers 0.000 claims abstract description 52
- 241000206672 Gelidium Species 0.000 claims abstract description 51
- 235000010419 agar Nutrition 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000012458 free base Substances 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 239000004615 ingredient Substances 0.000 claims abstract description 20
- 239000001913 cellulose Substances 0.000 claims abstract description 19
- 241000208125 Nicotiana Species 0.000 claims abstract description 17
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 16
- 229920002678 cellulose Polymers 0.000 claims abstract description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 39
- 239000003765 sweetening agent Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 25
- 235000003599 food sweetener Nutrition 0.000 claims description 23
- 239000002243 precursor Substances 0.000 claims description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000003755 preservative agent Substances 0.000 claims description 16
- 235000019264 food flavour enhancer Nutrition 0.000 claims description 14
- 235000010980 cellulose Nutrition 0.000 claims description 13
- 150000005846 sugar alcohols Chemical class 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 235000021092 sugar substitutes Nutrition 0.000 claims description 10
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- 239000000619 acesulfame-K Substances 0.000 claims description 9
- 235000019270 ammonium chloride Nutrition 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 potassium sorbate) Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims description 7
- 239000004302 potassium sorbate Substances 0.000 claims description 7
- 229940069338 potassium sorbate Drugs 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 235000019846 buffering salt Nutrition 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000845 maltitol Substances 0.000 claims description 5
- 235000010449 maltitol Nutrition 0.000 claims description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 5
- 229940035436 maltitol Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229920003124 powdered cellulose Polymers 0.000 claims description 5
- 235000019814 powdered cellulose Nutrition 0.000 claims description 5
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical class [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 239000004383 Steviol glycoside Substances 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 229940109275 cyclamate Drugs 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 150000002332 glycine derivatives Chemical class 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 150000002823 nitrates Chemical class 0.000 claims description 4
- 150000002826 nitrites Chemical class 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019204 saccharin Nutrition 0.000 claims description 4
- 229940081974 saccharin Drugs 0.000 claims description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 235000019411 steviol glycoside Nutrition 0.000 claims description 4
- 229930182488 steviol glycoside Natural products 0.000 claims description 4
- 150000008144 steviol glycosides Chemical class 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 239000000047 product Substances 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 21
- 238000009472 formulation Methods 0.000 description 17
- 210000000214 mouth Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002144 chemical decomposition reaction Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 235000014755 Eruca sativa Nutrition 0.000 description 2
- 244000024675 Eruca sativa Species 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940071207 sesquicarbonate Drugs 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019888 Vivapur Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000021091 sugar-based sweeteners Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
Definitions
- the present invention relates to tobacco-free or low-tobacco nicotine compositions.
- the compositions are preferably for human consumption, such as may be delivered orally by means of placing a permeable pouch filled with the compositions in the mouth of a user.
- Nicotine-loaded tobacco-free or low-tobacco pouches are replacement products that can help to alleviate cravings associated with smoking cigarettes, cigars, or other nicotine delivery products.
- nicotine-delivery systems based on inhalation i.e., so-called vaping
- nicotine vapor is quickly absorbed through the lungs into the blood stream, reaching the brain within ten seconds of inhalation. The latter produces a feeling of almost instantaneous satisfaction, that lasts also some time after smoking/inhalation.
- Nicotine-loaded tobacco-free or low-tobacco pouches are intended for use in the mouth by placing the pouch under the lip, thereby enabling the release and absorption of nicotine through oral mucosa.
- the pouches typically comprise a saliva permeable membrane material and contain particulate filler materials, nicotine or nicotine derivatives and other ingredients such as flavourings.
- the particulate materials may comprise inter alia polysaccharide or cellulose materials.
- Nicotine is an alkaloid, which was traditionally derived from tobacco leaves but may now also be provided in a fully synthetic form. It is available both as a free-base nicotine and in the form of different nicotine salts that are produced from the interaction between nicotine and an acid. Common nicotine salts include chloride, sulfate, benzoate, tartrate salts.
- the formulations contain significant quantities of buffering salts to increase the alkalinity of the formulation. Increased alkalinity shifts the dissociation constant of the nicotine such that the free base form is made in solution (such as in the mouth of the user) from the ionic form of nicotine in the salts.
- the uncharged free-base nicotine exhibits enhanced permeability across the oral mucosa into the blood stream compared to its ionic form, which is critical for consumer use.
- the pH of nicotine-loaded tobacco-free pouches ranges typically between 6.9 and 10.1, which translates into undissociated free-base nicotine levels between 7.7 to 99.2 %, respectively (Stanfil et al. Nicotine & Tobacco Research, 2021, 1590-1596).
- nicotine salt formulations tend to feature a low moisture content, i.e. less than 10wt%. (such as 1-8 wt%). This is because higher moisture content would stimulate the formation of free base nicotine in situ, which would in turn reduce the stability of the product because free base nicotine is volatile and labile to oxidative degradation.
- free base nicotine is volatile and labile to oxidative degradation.
- some formulations involve large quantities of sweetener (such as maltitol) to stimulate salivation.
- sweetener such as maltitol
- salivation the overproduction of saliva tends to result in users spitting or swallowing, impacting nicotine uptake.
- degradation of the product is indicative of reactivity in the system which may result in the presence of undesired (and potentially toxic) compounds.
- Formulations which have low moisture content can feel hard and unpalatable when in use, while high alkalinity (especially a pH greater than about 9) can be irritating to the gums of the user.
- moist nicotine products show enhanced palatability, i.e., soft and pleasant mouthfeel, when used in the mouth.
- Nicotine loaded pouches containing free-base nicotine products have been provided with moisture levels on upwards of 35 wt%.
- formulations of this type require stabilization to act against degradation of the nicotine and also require components to prevent moisture loss upon storage.
- moist free base nicotine products tend to require the use of a greater number and quantity of additives than those containing nicotine salts.
- WO 2010/104464 and WO 2010/0114445 disclose compositions of free-base nicotine that can be stabilized using a salt of alginic acid, such as sodium alginate (e.g., Protanal LFR 5/60).
- a salt of alginic acid such as sodium alginate (e.g., Protanal LFR 5/60).
- the amount of sodium alginate used as a stabilizer is substantial, typically corresponding to nicotine:Protanal 1 :2 ratio (wt).
- WO2020244721 discloses a composition of free-base nicotine wherein the latter is stabilized using an ion exchange resin, e.g., polacrilex resin, such as Amberlite IRP64 (methacrylic acid polymer with divinylbenzene, or potassium salt of the latter).
- the amount of polacrilex resin used as a nicotine stabilizer is in a nicotine-to-resin ratio which may vary between 1 : 1.19 and 1:4. It is to be understood that polymers having some carboxylate groups are typically used to stabilise free-base nicotine.
- humectants such as sugar alcohols.
- US 2020/0383372 discloses several compositions of free-base nicotine with polacrilex resin having a moisture content above 15%, most commonly around 30%.
- the humectants of choice include sugar alcohols from glycerol, propylene glycol, polyethylene glycol, alginate, pectin, xanthan gum, modified starch, hydroxypropyl cellulose, and triacetin.
- the moisture present in the product poses significant challenges for formulation.
- Moisture acts not only as a nicotine solvent that facilitates diffusive transport from formulation to the oral mucosa but also a medium for chemical reactions that can significantly accelerate the rate of chemical degradation and product spoilage.
- high moisture content nicotine formulations may still be unstable, especially if the moisture content exceeds 30% wt.
- degradation of nicotine causes discoloration of the product.
- Physical instability is also a common problem of moist products. Physical instability may include discoloration, stickiness, lumping, phase transitions, such as dissolutionrecrystallization and evaporation. Discoloration and chemical degradation may be connected to each other. Lumping of powder may require additional sieving for particle size control after compounding, which results in additional costs during processing.
- the physical and chemical instability may lead to accumulation of toxic by-products of nicotine degradation as well as negative product experiences due to color changes (white product turning yellow, brown, or pink), dusting due to drying and leakage through pouch, product hardening and deteriorated mouthfeel as well as altered nicotine release profile.
- the present invention provides A composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar and/or derivatives of agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%. All wt% are expressed as a percentage of weight the composition as a whole.
- the invention provides the use as a nicotine release control agent of agar agar in a composition
- a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.
- the invention provides the use as a nicotine stabilising agent of agar agar in a composition
- a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.
- the composition further comprises additional ingredients, in an amount from about 1 wt% to about 10 wt% or more preferably in an amount from about 1 wt% to about 8 wt%.
- additional ingredients may comprise one or more additives selected from flavourings, flavour enhancers, sweeteners and preservatives.
- Sweeteners are preferably present in an amount from about lwt% to about 3 wt %.
- the sweeteners may comprise compounds selected from sugars (such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose), sugar alcohols (such as xylitol, maltitol, sorbitol, erythritol) and/or sugar substitutes (such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides).
- sugars such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose
- sugar alcohols such as xylitol, maltitol, sorbitol, erythritol
- sugar substitutes such as aspartame, saccharin, sucralose, allulose, acesulfame K
- the sweeteners include a sugar alcohol in an amount less than 3 wt%, preferably less than 2 wt%, such as between 1 wt% and 2 wt%. Additionally or alternatively, the sweetener may comprise a sugar substitute in an amount less than 1 wt%, preferably less than 0.5 wt%, such as between 0.05 wt% and 0.3 wt%.
- Preferred sweeteners include xylitol and/or acesulfame K.
- Preservatives may comprise one or more preservatives selected from calcium chloride, salts of sorbic acid (such as potassium sorbate), salts of benzoic acid (such as sodium benzoate), nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts.
- preservatives are in an amount less than about lwt%, preferably between 0.1wt% and 0.5wt%, such as between about 0.25wt% and about 0.35wt%.
- the pH control salts may comprise buffering salts such as carbonate or sesquicarbonate salts; acetate salts, glycinate, acetate, glycinate, gluconate, borate, glycerophosphate or citrate salts; phosphate salts.
- buffering salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- acetate salts such as carbonate or sesquicarbonate salts
- sodium bicarbonate may be in an amount between less than lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.2 wt% and 0.3 wt%.
- the composition contains greater than 40wt% water, for example between 40 wt% and 50 wt% water, preferably between about 44 wt% and about 48 wt% water.
- the native cellulose material comprises powdered cellulose and/or microcrystalline cellulose (MCC), with MCC being preferred.
- MCC microcrystalline cellulose
- the release control agent preferably comprises agar agar in an amount less than about lwt%, preferably less than 0.7wt% of the composition.
- the release control agent may comprise agar agar in an amount from about 0.2 wt% to about 0.7wt%, preferably in an amount from about 0.2wt% to about 0.5wt%.
- the ratio of agar agar to nicotine is preferably less than about 1.3: 1. In further preferred embodiments, the ratio of agar agar to nicotine is from about 0.1 : 1 to about 1.2: 1, preferably from about 0.1 : 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1.
- Some embodiments may include tobacco leaf in an amount less than 5 wt%, preferably about 1 wt% to 3 wt%.
- the pH of the composition is from 6 to 9, preferably from 7 to 9 and more preferably from 7 to 8.5.
- any flavour enhancers present are selected from the group comprising sodium chloride, glutamate salts, glycine salts, inosinic acid salts and 5'-ribonucleotide salts.
- sodium chloride it is preferred to be in an amount less than 8 wt%, preferably between 1 wt% and 7 wt% by weight of the composition.
- the composition preferably includes flavouring compounds in an amount less than about 5 wt% of the total composition, for example less than 3 wt% of the composition or between 0.5 wt% and 3 wt% of the composition.
- Preferred quantities of nicotine in the composition are between 0.2wt% and 3 wt%, or between 0.2wt% and 2wt%.
- the composition may consist essentially of the components described above.
- the invention provides a water or saliva permeable pouch containing a composition as described above.
- the invention provides a package containing a plurality of those pouches.
- the invention provides a process for forming a nicotine containing composition, such as that which is described above, the process comprising: a. combining in a mixer native cellulose material in an amount 40 wt% to 60 wt% of the intended composition with agar agar powder in an amount 0.2 wt% to 2 wt% of the intended composition, thereby to form a precursor composition; b. adding water to the precursor composition and mixing at a temperature greater than 50°C; c. adding to the precursor composition nicotine in free base form, in an amount 0.2wt% to about 2wt% of the intended final composition, while the temperature is greater than 50°C; d. allowing the mixture to cool. additional water may be added between steps (c) and (d).
- the mixing of the precursor is at a temperature greater than about 60°C, preferably above about 70°C, preferably above 80°C.
- step (b) the water may be provided to the precursor at a temperature above about 70°C, preferably above about 80°C. Indeed, in step (b) the water may be provided to the precursor is in the form of steam or vapour.
- steps (c) and (d) may be at a temperature greater than about 70°C, preferably above about 80°C. Indeed, it may be in the form of steam or vapour.
- the precursor mixture is heated while in the mixer, for example during step (b) and/or (c) and or during or after any addition of water following step (c).
- further water is added to the composition after step (d).
- any of the following components may be added to the precursor mixture prior to step (b): e. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt% of the intended composition; f. additional ingredients, preferably in an amount up to about 12 wt% of the intended composition.
- Agar agar is a dried, hydrophilic, colloidal polysaccharide complex extracted from red algae (Rhodophyceae). The structure is believed to be a complex range of polysaccharide chains having alternating a-(1 ⁇ 3) and g-(1 ⁇ 4) linkages.
- Agar agar can be separated into a natural gelling fraction, agarose, and a sulphated nongelling fraction, agaropectin.
- Agar agar is soluble in hot water to form a viscous solution but has poor solubility in cold water and ethanol (95%). A 1% w/v aqueous solution forms a stiff jelly on cooling.
- tobacco any part, such as leaves, stems, and stalks, of any member of the genus Nicotiana.
- the tobacco may be whole, shredded, threshed, cut, ground, cured, aged, fermented, or treated otherwise, e.g., granulated or encapsulated.
- Figure 1 shows a plot of nicotine release profiles for a composition according to the present invention and comparative examples
- Figure 2 shows a plot of nicotine release profiles for a composition according to the present invention and comparative examples
- Figure 3 shows photographs of a pouch and composition according to the present invention and comparative examples.
- a tobacco free (or in some instances low tobacco) nicotine formulation for use in pouches for oral use.
- the formulation has a high water content and contains nicotine in its free base form.
- the composition involves a cellulosic filler and also the use of agar agar as a nicotine release agent to promote the release of nicotine from the composition when it is placed (e.g. in a pouch) in the oral cavity of a user.
- the composition has a general formulation as described below: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. A native cellulose material, such as microcrystalline cellulose, in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts, such as a combination of ammonium chloride and sodium bicarbonate in an amount from about 1 wt% to about 6 wt%; e. a release control agent comprising agar agar or a derivative thereof in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, such as flavourings, flavour enhancers, sweeteners and preservatives, preferably in an amount up to about 12 wt%.
- additional ingredients such as flavourings, flavour enhancers, sweeteners and preservatives, preferably in an amount up to about 12 wt%.
- All wt% are based on the total weight of the composition.
- the quantity of nicotine in the composition varies by the desired strength of the product. In some embodiments the quantity of nicotine is between 0.2wt% and 3 wt%, or between 0.2wt% and 2wt%.
- the native cellulose useful in the present invention may comprise powdered cellulose and/or microcrystalline cellulose.
- powdered cellulose which may be used in te invention include Arbocel(RTM) as supplied by J. Rettenmaier & Sbhne GmbH; Elcema; KC Flock(RTM) supplied by Nippon Paper Industries Co. Ltd.; Microcel 3E-150 supplied by Roquette Freres; Sanacel (RTM) supplied by CFF GmbH; Sanacel Pharma (RTM) supplied by CFF GmbH; Sancel-W supplied by NB Entrepreneurs Company; or Solka-Floc (RTM) supplied by J. Rettenmaier USA LP.
- microcrystalline cellulose examples include Avicel (RTM) PH supplied by Dupont Nutrition and Biosciences, Inc.; Cellets (RTM) supplied by Pharmatrans Sanaq AG; Celphere (TM) supplied by Asahi Kasei Corporation; Ceolus (TM) KG supplied by Asahi Kasei Corporation; Emcocel (RTM) supplied by JRS Pharma GmbH; MCC Sanaq (RTM) supplied by Pharmatrans Sanaq AG; Pharmacel (RTM) supplied by DFE Pharma GmbH; Tabulose (RTM) supplied by Roquette Freres; Vivapur (RTM) supplied by JRS Pharma GmbH.
- the water content of the composition should be at least 35wt%, it is preferred that a greater proportion of water is contained in the composition. Greater palatability for the user, including greater softness, tends to be found when the water content of the composition is greater than 40 wt%.
- Preferred compositions have a water content greater than 42 wt%, for example between 44 wt% and 48 wt% water.
- the composition contains pH control salts to provide optimum pH of the composition while in use in the mouth of a user. It is preferred that the pH of the composition, when measured according to the Coresta Method No.69, 2017, is from 6 to 9, preferably from 7 to 9 and more preferably from 7 to 8.5. This can be achieved by providing pH adjusting agents such as sodium bicarbonate or buffering salts such as a combination of a ammonium chloride and sodium bicarbonate. Typical quantities of pH control salts are between 0.2wt% and 2wt%, preferably between 0.2 wt% and 1 wt%.
- Alternative buffering salts may be selected from e.g. carbonate or sesquicarbonate salts; acetate salts, glycinate, acetate, glycinate, gluconate, borate, glycerophosphate or citrate salts; phosphate salts.
- Flavourings contained within the composition are not limited but preferably include flavonoid compounds to stimulate the olefactory system of the user, typically in an amount of less than about 3wt% of the total composition. Such compounds are commercially available and are well known to those skilled in the art.
- flavour of the composition may be improved by the inclusion of sweeteners or flavour enhancers.
- Sweeteners may include sugar based sweeteners such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose; sugar alcohols such as xylitol, maltitol, sorbitol, erythritol; or other sugar substitutes such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides.
- the sweeteners may be present alone though are preferably used in combination (for example a sugar alcohol and a sugar substitute). A preferred combination is xylitol and acesulfame K. Quantities of the sweetener present in the composition depend on the properties of the sweeteners chosen, as would be understood by a person skilled in the art but typically range between 1 wt% and 3 wt% in total.
- Flavour enhancers may include sodium chloride, salts of glutamic acid (such as sodium glutamate), glycine salts, inosinic acid salts and 5'-ribonucleotide salts (such as on or more disodium ribonucleotides). Quantities of the flavour enhancer present in the composition depend on the properties of the flavour enhancer chosen, as would be understood by a person skilled in the art but typically range between 1 wt% and 8 wt% in total.
- Preservatives may include antimicrobial preservatives such as sorbic acid salts (such as sodium or potassium sorbate), benzoic acid salts, nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts. Salts such as calcium chloride may also be used as preservatives. All compositions may contain a small quantity of tobacco, such as between 1 wt% and 5 wt%, especially when contained in a pouch.
- antimicrobial preservatives such as sorbic acid salts (such as sodium or potassium sorbate), benzoic acid salts, nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts. Salts such as calcium chloride may also be used as preservatives. All compositions may contain a small quantity of tobacco, such as between 1 wt% and 5 wt%, especially when contained in a pouch.
- agar agar in the composition acts as an effective nicotine stabilizer and release control agent.
- the nicotine may be partially bound within an agar agar gel which may be formed during manufacture. This appears to provide both a highly stable nicotine composition, which despite the use of free base nicotine and high levels of moisture is able to maintain a long shelf life.
- the nicotine release profile of the composition is fast and consistent, providing excellent product performance.
- the agar agar is preferably present in an amount from 0.1wt% to about 1.2 wt%. It is preferably present in a ratio of agar agar to nicotine of 0.1 : 1 to about 1.2: 1, preferably from about 0.1 : 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1. This is a significantly lower ratio than would be required for prior art stabilizing agents.
- Any food or pharmaceutical grade agar agar may be utilized in the present invention.
- Specific examples include Rokoagar (RTM) RGM 600 and RGM 800, as supplied by Industries Roko, S.A..
- the composition may have a general composition as follows: a. From about 0.2wt% to about 3wt% nicotine in free base form; b. Microcrystalline cellulose, in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt% and preferably above 40 wt%; d. buffer salts ammonium chloride in an amount 0.05 wt% and lwt% and sodium bicarbonate in an amount from about 0.1 wt% to about 1 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, such as a.
- flavourings in an amount from 0.5 wt% to about 3 wt%
- flavour enhancers such as sodium chloride in an amount between 2wt% and 8wt%
- sweeteners such as xylitol in an amount from about between 1 wt% and 2 wt% and/or acesulfame K in an amount from 0.05 wt% to 1 wt%
- preservatives such as potassium sorbate in an amount from about 0.25 wt% to about 1 wt%.
- tobacco in a quantity from 0 wt% to 3 wt%.
- a process for the manufacture of tobacco -free or low-tobacco nicotine compositions involves the mixing in a vessel (such as an autoclave) the native cellulose in a portion of from 30 wt% to 60 wt% of the intended final composition and agar agar in a portion of from 0.1 wt% to 2 wt% of the final composition, each in powder or granular form.
- a vessel such as an autoclave
- the native cellulose in a portion of from 30 wt% to 60 wt% of the intended final composition and agar agar in a portion of from 0.1 wt% to 2 wt% of the final composition, each in powder or granular form.
- agar agar in a portion of from 0.1 wt% to 2 wt% of the final composition, each in powder or granular form.
- One or more of the other solid components of the composition such as pH control salts, flavour enhancers, sweeteners or preservatives may also be
- At least a portion of the water (preferably at least 10wt% of the intended final composition) is then added to the composition and the composition is heated.
- the heating may take place in a number of ways.
- the mixing vessel may be heated, for example by use of a heating manifold.
- the water may be heated prior to its introduction to the mixing vessel or some or all of the water may be added as steam.
- the temperature of the resulting precursor mixture should be at least 50°C, preferably at least 60°C and more preferably at least 70°C.
- the precursor is heated such that the agar agar at least partially dissolves in the water.
- the low concentration of agar agar coupled with shear applied during mixing sufficient dissolution of agar agar may be obtained at such temperatures.
- the nicotine is added to the precursor in an amount from 0.2 wt% to 2 wt% of the final composition.
- other liquid components of the composition such as flavourings, may be added.
- a second portion of water (preferably at least 10wt% of the intended final composition) is then added to the composition and the composition is heated, again to at least 50°C, preferably at least 60°C and more preferably at least 70°C.
- the precursor is then allowed to cool, preferably while mixing is continued.
- the resulting composition may be set aside. Without wishing to be bound by any particular theory, it is believed that the agar agar forms a gel which at least partially encapsulates the nicotine which is present, stabilizing it and also providing excellent release properties.
- the resulting composition may have further water added to it, preferably with the water at ambient temperature. This step is to afford a greater content to the composition where required.
- flavour enhancers, sweeteners or preservatives may be added at this stage, additionally to or in the alternative to their addition earlier in the process.
- the finished composition may optionally be mixed with tobacco in an amount of up to 5 wt% of the final composition.
- the composition is soft to the touch, produces little dust and does not form clumps.
- the product is white in colour. In preferred embodiments, it is packed into saliva permeable pouches ready for oral delivery.
- compositions were produced according to the method described above. 0.7g portions of each of the finished compositions were packed into a saliva permeable pouch and tested according to the following release test:
- a single person avoids nicotine intake for 10 hours before the experiment starts and avoids food or drink intake 1 hour before the experiment starts. Prior to the procedure, the testing person rinses his or her mouth with water and waits for 10 minutes.
- a pouch is taken and the weight is measured before being placed under the lip of the testing person.
- the pouch is kept in place, without moving, for 5 minutes.
- the pouch is then removed and placed in a 50cm3 distilled water and stirred or shaken for 30 minutes.
- a sample is taken and analysed for its nicotine content using HPLC.
- the tester then waits at least one hour before repeating the experiment, holding the pouch in place for 10, 20, 30 and 40 minutes on successive repeats.
- Example 2 Further compositions, identical to those of Example 1 but which comprised different stabilizers in place of agar agar were prepared and tested according to the same method.
- the stabilizers used in these examples are shown in the table below:
- a pH electrode is calibrated using at least two pH buffers (4,00 and 7,00 or 7,00 and 10,00) to produce a two-point calibration that will cover the pH range of the products tested. Calibration is performed in conjunction with the measurements of the samples and at 23°C. The calibration slope must be within 95 % - 105 % before the electrode can be used for sample measurements. The electrode must be rinsed, before and after each measurement, with water.
- the samples for testing are allowed to reach room temperature before preparation. Samples are then mixed with water at a concentration of 5 wt% and shaken or stirred for 30 minutes. The pH electrode is then used to determine the pH of the water in the sample mixture.
- Comparative examples 10-12 list commercial products which are based on a nicotine salt and featuring low moisture content, i.e., below 10% wt. These products generally feature long shelf life of at least 12 months. However, miscoloration and lumpiness increase with increasing moisture content. Very dry products may dust during storage and be difficult to handle during packaging. Low moisture products typically feature poor palatability (dry mouthfeel) and show delayed nicotine release. The appearance of samples is presented in Figure 3.
- Comparative examples 13-17 list commercial products based on a nicotine free-base and featuring high moisture content, i.e., above 40% wt. Lumpiness and various degrees of miscoloration are characteristic to nearly all products. Comparative Examples 13 to 16 are variations of the same product from the same manufacturer, that vary mainly with respect to aromas, release modifiers, and sweeteners used. The products in these examples contain calcium chloride. Typically, calcium chloride is used as excipient with water binding properties and as antimicrobial preservative. The appearance of samples is presented in Figure 3. Comparative Example 13
- Comparative examples 18 and 19 list commercial products based on free-base nicotine and featuring medium moisture content, i.e., below 10-30% wt. These products feature a shelf life of around 6-12 months. Both products exhibit signs of miscoloration and lumpiness. Comparative Example 16, rich in sugar alcohol, is especially prone to form lumps, which harden over time, thereby significantly decreasing product palatability. The appearance of samples is presented in Figure 3.
- Example 2 represent an example of formulation according to the present invention.
- the product features high moisture content and high nicotine stability during at least 12 months of storage. No signs of miscoloration, lumping or dusting are observed after storage.
- Example 2 The Examples show that compositions of the present invention provide a soft, white product that avoids clumping and is thus palatable to use and easy to pack and manufacture. It also has a substantial shelf life and delivers nicotine quickly and consistently to the user.
Abstract
The present invention describes a composition, such as a tobacco free or low tobacco nicotine containing composition, comprising: a. From about 0.2wt% to about 2wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%. The composition may be provided in pouches for oral delivery to a user.
Description
Nicotine Composition
The present invention relates to tobacco-free or low-tobacco nicotine compositions. The compositions are preferably for human consumption, such as may be delivered orally by means of placing a permeable pouch filled with the compositions in the mouth of a user.
Nicotine-loaded tobacco-free or low-tobacco pouches are replacement products that can help to alleviate cravings associated with smoking cigarettes, cigars, or other nicotine delivery products. When smoking cigarettes or using nicotine-delivery systems based on inhalation, i.e., so-called vaping, nicotine vapor is quickly absorbed through the lungs into the blood stream, reaching the brain within ten seconds of inhalation. The latter produces a feeling of almost instantaneous satisfaction, that lasts also some time after smoking/inhalation.
Nicotine-loaded tobacco-free or low-tobacco pouches are intended for use in the mouth by placing the pouch under the lip, thereby enabling the release and absorption of nicotine through oral mucosa. The pouches typically comprise a saliva permeable membrane material and contain particulate filler materials, nicotine or nicotine derivatives and other ingredients such as flavourings. The particulate materials may comprise inter alia polysaccharide or cellulose materials.
Nicotine is an alkaloid, which was traditionally derived from tobacco leaves but may now also be provided in a fully synthetic form. It is available both as a free-base nicotine and in the form of different nicotine salts that are produced from the interaction between nicotine and an acid. Common nicotine salts include chloride, sulfate, benzoate, tartrate salts.
It is known to provide tobacco-free or low-tobacco pouches where nicotine is provided in salt form in a powder formulation. The provision of nicotine salts in such formulations is deployed in part because of the high degree of stability of the system toward chemical degradation and/or evaporation.
In order to provide the egress of free base nicotine from formulations involving nicotine salts, the formulations contain significant quantities of buffering salts to increase the alkalinity of the formulation. Increased alkalinity shifts the dissociation constant of the nicotine such that the free base form is made in solution (such as in the mouth of the user) from the ionic form of nicotine in the salts. The uncharged free-base nicotine exhibits
enhanced permeability across the oral mucosa into the blood stream compared to its ionic form, which is critical for consumer use.
In particular, the pH of nicotine-loaded tobacco-free pouches ranges typically between 6.9 and 10.1, which translates into undissociated free-base nicotine levels between 7.7 to 99.2 %, respectively (Stanfil et al. Nicotine & Tobacco Research, 2021, 1590-1596).
It follows that nicotine salt formulations tend to feature a low moisture content, i.e. less than 10wt%. (such as 1-8 wt%). This is because higher moisture content would stimulate the formation of free base nicotine in situ, which would in turn reduce the stability of the product because free base nicotine is volatile and labile to oxidative degradation. When nicotine oxidises it produces a yellow-brown coloration which is often unappealing to consumers and also produces an unpleasant taste. Indeed, some formulations involve large quantities of sweetener (such as maltitol) to stimulate salivation. However the overproduction of saliva tends to result in users spitting or swallowing, impacting nicotine uptake. Moreover, degradation of the product is indicative of reactivity in the system which may result in the presence of undesired (and potentially toxic) compounds.
These requirements provide problems for the user. Formulations which have low moisture content can feel hard and unpalatable when in use, while high alkalinity (especially a pH greater than about 9) can be irritating to the gums of the user. In contrast, moist nicotine products show enhanced palatability, i.e., soft and pleasant mouthfeel, when used in the mouth.
Nicotine loaded pouches containing free-base nicotine products have been provided with moisture levels on upwards of 35 wt%. However, formulations of this type require stabilization to act against degradation of the nicotine and also require components to prevent moisture loss upon storage. As such, moist free base nicotine products tend to require the use of a greater number and quantity of additives than those containing nicotine salts.
WO 2010/104464 and WO 2010/0114445 disclose compositions of free-base nicotine that can be stabilized using a salt of alginic acid, such as sodium alginate (e.g., Protanal LFR 5/60). The amount of sodium alginate used as a stabilizer is substantial, typically corresponding to nicotine:Protanal 1 :2 ratio (wt). WO2020244721 discloses a composition of free-base nicotine wherein the latter is stabilized using an ion exchange resin, e.g., polacrilex resin, such as Amberlite IRP64 (methacrylic acid polymer with divinylbenzene, or potassium salt of the latter). The amount of polacrilex resin used as a nicotine stabilizer
is in a nicotine-to-resin ratio which may vary between 1 : 1.19 and 1:4. It is to be understood that polymers having some carboxylate groups are typically used to stabilise free-base nicotine.
To prevent the loss of moisture in free-base nicotine formulations upon storage, it is common to use humectants such as sugar alcohols. US 2020/0383372 discloses several compositions of free-base nicotine with polacrilex resin having a moisture content above 15%, most commonly around 30%. The humectants of choice include sugar alcohols from glycerol, propylene glycol, polyethylene glycol, alginate, pectin, xanthan gum, modified starch, hydroxypropyl cellulose, and triacetin.
However, the moisture present in the product poses significant challenges for formulation. Moisture acts not only as a nicotine solvent that facilitates diffusive transport from formulation to the oral mucosa but also a medium for chemical reactions that can significantly accelerate the rate of chemical degradation and product spoilage. Indeed, high moisture content nicotine formulations may still be unstable, especially if the moisture content exceeds 30% wt. As described above, degradation of nicotine causes discoloration of the product. Furthermore, it is important to avoid nicotine degradation and to prevent moisture evaporation during storage, which may cause discrepancy between the factual and stated nicotine loading (mg nicotine per g). This reduces the shelf life of the product.
Physical instability is also a common problem of moist products. Physical instability may include discoloration, stickiness, lumping, phase transitions, such as dissolutionrecrystallization and evaporation. Discoloration and chemical degradation may be connected to each other. Lumping of powder may require additional sieving for particle size control after compounding, which results in additional costs during processing.
The physical and chemical instability may lead to accumulation of toxic by-products of nicotine degradation as well as negative product experiences due to color changes (white product turning yellow, brown, or pink), dusting due to drying and leakage through pouch, product hardening and deteriorated mouthfeel as well as altered nicotine release profile.
There is therefore a need to provide tobacco-free or low-tobacco nicotine compositions which are suitable for use in pouches and in which the nicotine has a high degree of chemical stability, the composition has a high degree of physical stability, the pH is at a level which is comfortable for the user and which contains a relatively high degree of moisture.
There is a further need to provide a moist tobacco-free or low-tobacco nicotine composition to provide both fast nicotine release (and thus fast absorption to the blood stream) and to enhance the overall organoleptic experience of the user.
There is a further need to provide such products which may be produced in a simple, reliable and cost efficient manner.
In a first aspect, the present invention provides A composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar and/or derivatives of agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%. All wt% are expressed as a percentage of weight the composition as a whole.
In a second aspect, the invention provides the use as a nicotine release control agent of agar agar in a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.
In a third aspect, the invention provides the use as a nicotine stabilising agent of agar agar in a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%;
d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.
Preferably, the composition further comprises additional ingredients, in an amount from about 1 wt% to about 10 wt% or more preferably in an amount from about 1 wt% to about 8 wt%. The additional ingredients may comprise one or more additives selected from flavourings, flavour enhancers, sweeteners and preservatives.
Sweeteners are preferably present in an amount from about lwt% to about 3 wt %. The sweeteners may comprise compounds selected from sugars (such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose), sugar alcohols (such as xylitol, maltitol, sorbitol, erythritol) and/or sugar substitutes (such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides).
Preferaby, the sweeteners include a sugar alcohol in an amount less than 3 wt%, preferably less than 2 wt%, such as between 1 wt% and 2 wt%. Additionally or alternatively, the sweetener may comprise a sugar substitute in an amount less than 1 wt%, preferably less than 0.5 wt%, such as between 0.05 wt% and 0.3 wt%. Preferred sweeteners include xylitol and/or acesulfame K.
Preservatives may comprise one or more preservatives selected from calcium chloride, salts of sorbic acid (such as potassium sorbate), salts of benzoic acid (such as sodium benzoate), nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts. Preferably, preservatives are in an amount less than about lwt%, preferably between 0.1wt% and 0.5wt%, such as between about 0.25wt% and about 0.35wt%.
The pH control salts may comprise buffering salts such as carbonate or sesquicarbonate salts; acetate salts, glycinate, acetate, glycinate, gluconate, borate, glycerophosphate or citrate salts; phosphate salts. Preferred is a combination of ammonium chloride and sodium bicarbonate. Where ammonium chloride is present it may be in an amount between 0.05 wt% and lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.15 wt% and 0.25 wt%. Where sodium bicarbonate is present it may be in an amount between less than lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.2 wt% and 0.3 wt%.
Preferably, the composition contains greater than 40wt% water, for example between 40 wt% and 50 wt% water, preferably between about 44 wt% and about 48 wt% water.
Preferably, the native cellulose material comprises powdered cellulose and/or microcrystalline cellulose (MCC), with MCC being preferred.
The release control agent preferably comprises agar agar in an amount less than about lwt%, preferably less than 0.7wt% of the composition. Indeed, the release control agent may comprise agar agar in an amount from about 0.2 wt% to about 0.7wt%, preferably in an amount from about 0.2wt% to about 0.5wt%.
The ratio of agar agar to nicotine is preferably less than about 1.3: 1. In further preferred embodiments, the ratio of agar agar to nicotine is from about 0.1 : 1 to about 1.2: 1, preferably from about 0.1 : 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1.
Some embodiments may include tobacco leaf in an amount less than 5 wt%, preferably about 1 wt% to 3 wt%.
It is preferred that the pH of the composition, as measured by Coresta Method No.69, 2017, is from 6 to 9, preferably from 7 to 9 and more preferably from 7 to 8.5.
Preferably, any flavour enhancers present are selected from the group comprising sodium chloride, glutamate salts, glycine salts, inosinic acid salts and 5'-ribonucleotide salts. Where sodium chloride is present, it is preferred to be in an amount less than 8 wt%, preferably between 1 wt% and 7 wt% by weight of the composition.
The composition preferably includes flavouring compounds in an amount less than about 5 wt% of the total composition, for example less than 3 wt% of the composition or between 0.5 wt% and 3 wt% of the composition.
Preferred quantities of nicotine in the composition are between 0.2wt% and 3 wt%, or between 0.2wt% and 2wt%.
In some embodiments, the composition may consist essentially of the components described above.
In another aspect, the invention provides a water or saliva permeable pouch containing a composition as described above. In a still further aspect, the invention provides a package containing a plurality of those pouches.
In a further aspect, the invention provides a process for forming a nicotine containing composition, such as that which is described above, the process comprising: a. combining in a mixer native cellulose material in an amount 40 wt% to 60 wt% of the intended composition with agar agar powder in an amount 0.2 wt% to 2 wt% of the intended composition, thereby to form a precursor composition; b. adding water to the precursor composition and mixing at a temperature greater than 50°C; c. adding to the precursor composition nicotine in free base form, in an amount 0.2wt% to about 2wt% of the intended final composition, while the temperature is greater than 50°C; d. allowing the mixture to cool. additional water may be added between steps (c) and (d).
In preferred embodiments, in steps (b) and (c), the mixing of the precursor is at a temperature greater than about 60°C, preferably above about 70°C, preferably above 80°C.
In step (b) the water may be provided to the precursor at a temperature above about 70°C, preferably above about 80°C. Indeed, in step (b) the water may be provided to the precursor is in the form of steam or vapour.
Where additional water is added between steps (c) and (d) it may be at a temperature greater than about 70°C, preferably above about 80°C. Indeed, it may be in the form of steam or vapour.
In some embodiments, the precursor mixture is heated while in the mixer, for example during step (b) and/or (c) and or during or after any addition of water following step (c).
In some embodiments, further water is added to the composition after step (d).
In preferred embodiments, any of the following components may be added to the precursor mixture prior to step (b): e. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt% of the intended composition;
f. additional ingredients, preferably in an amount up to about 12 wt% of the intended composition.
Agar agar is a dried, hydrophilic, colloidal polysaccharide complex extracted from red algae (Rhodophyceae). The structure is believed to be a complex range of polysaccharide chains having alternating a-(1^3) and g-(1^4) linkages. Agar agar can be separated into a natural gelling fraction, agarose, and a sulphated nongelling fraction, agaropectin. Agar agar is soluble in hot water to form a viscous solution but has poor solubility in cold water and ethanol (95%). A 1% w/v aqueous solution forms a stiff jelly on cooling.
Where the term "tobacco" is used, we mean any part, such as leaves, stems, and stalks, of any member of the genus Nicotiana. The tobacco may be whole, shredded, threshed, cut, ground, cured, aged, fermented, or treated otherwise, e.g., granulated or encapsulated.
Embodiments of the present invention will now be described with reference to the following drawings:
Figure 1 shows a plot of nicotine release profiles for a composition according to the present invention and comparative examples;
Figure 2 shows a plot of nicotine release profiles for a composition according to the present invention and comparative examples;
Figure 3 shows photographs of a pouch and composition according to the present invention and comparative examples.
In a first embodiment of the present invention there is provided a tobacco free (or in some instances low tobacco) nicotine formulation for use in pouches for oral use. The formulation has a high water content and contains nicotine in its free base form. The composition involves a cellulosic filler and also the use of agar agar as a nicotine release agent to promote the release of nicotine from the composition when it is placed (e.g. in a pouch) in the oral cavity of a user.
In an embodiment, the composition has a general formulation as described below: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. A native cellulose material, such as microcrystalline cellulose, in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%;
d. one or more pH control salts, such as a combination of ammonium chloride and sodium bicarbonate in an amount from about 1 wt% to about 6 wt%; e. a release control agent comprising agar agar or a derivative thereof in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, such as flavourings, flavour enhancers, sweeteners and preservatives, preferably in an amount up to about 12 wt%.
All wt% are based on the total weight of the composition.
The quantity of nicotine in the composition varies by the desired strength of the product. In some embodiments the quantity of nicotine is between 0.2wt% and 3 wt%, or between 0.2wt% and 2wt%.
The native cellulose useful in the present invention may comprise powdered cellulose and/or microcrystalline cellulose. Examples of powdered cellulose which may be used in te invention include Arbocel(RTM) as supplied by J. Rettenmaier & Sbhne GmbH; Elcema; KC Flock(RTM) supplied by Nippon Paper Industries Co. Ltd.; Microcel 3E-150 supplied by Roquette Freres; Sanacel (RTM) supplied by CFF GmbH; Sanacel Pharma (RTM) supplied by CFF GmbH; Sancel-W supplied by NB Entrepreneurs Company; or Solka-Floc (RTM) supplied by J. Rettenmaier USA LP.
Examples of microcrystalline cellulose which may be used in the invention include Avicel (RTM) PH supplied by Dupont Nutrition and Biosciences, Inc.; Cellets (RTM) supplied by Pharmatrans Sanaq AG; Celphere (TM) supplied by Asahi Kasei Corporation; Ceolus (TM) KG supplied by Asahi Kasei Corporation; Emcocel (RTM) supplied by JRS Pharma GmbH; MCC Sanaq (RTM) supplied by Pharmatrans Sanaq AG; Pharmacel (RTM) supplied by DFE Pharma GmbH; Tabulose (RTM) supplied by Roquette Freres; Vivapur (RTM) supplied by JRS Pharma GmbH.
While the water content of the composition should be at least 35wt%, it is preferred that a greater proportion of water is contained in the composition. Greater palatability for the user, including greater softness, tends to be found when the water content of the composition is greater than 40 wt%. Preferred compositions have a water content greater than 42 wt%, for example between 44 wt% and 48 wt% water.
The composition contains pH control salts to provide optimum pH of the composition while in use in the mouth of a user. It is preferred that the pH of the composition, when measured according to the Coresta Method No.69, 2017, is from 6 to 9, preferably from 7
to 9 and more preferably from 7 to 8.5. This can be achieved by providing pH adjusting agents such as sodium bicarbonate or buffering salts such as a combination of a ammonium chloride and sodium bicarbonate. Typical quantities of pH control salts are between 0.2wt% and 2wt%, preferably between 0.2 wt% and 1 wt%. Alternative buffering salts may be selected from e.g. carbonate or sesquicarbonate salts; acetate salts, glycinate, acetate, glycinate, gluconate, borate, glycerophosphate or citrate salts; phosphate salts.
Flavourings contained within the composition are not limited but preferably include flavonoid compounds to stimulate the olefactory system of the user, typically in an amount of less than about 3wt% of the total composition. Such compounds are commercially available and are well known to those skilled in the art.
The flavour of the composition may be improved by the inclusion of sweeteners or flavour enhancers.
Sweeteners may include sugar based sweeteners such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose; sugar alcohols such as xylitol, maltitol, sorbitol, erythritol; or other sugar substitutes such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides. The sweeteners may be present alone though are preferably used in combination (for example a sugar alcohol and a sugar substitute). A preferred combination is xylitol and acesulfame K. Quantities of the sweetener present in the composition depend on the properties of the sweeteners chosen, as would be understood by a person skilled in the art but typically range between 1 wt% and 3 wt% in total.
Flavour enhancers may include sodium chloride, salts of glutamic acid (such as sodium glutamate), glycine salts, inosinic acid salts and 5'-ribonucleotide salts (such as on or more disodium ribonucleotides). Quantities of the flavour enhancer present in the composition depend on the properties of the flavour enhancer chosen, as would be understood by a person skilled in the art but typically range between 1 wt% and 8 wt% in total.
Preservatives may include antimicrobial preservatives such as sorbic acid salts (such as sodium or potassium sorbate), benzoic acid salts, nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts. Salts such as calcium chloride may also be used as preservatives.
All compositions may contain a small quantity of tobacco, such as between 1 wt% and 5 wt%, especially when contained in a pouch.
The inventors have surprisingly found that the presence of agar agar in the composition acts as an effective nicotine stabilizer and release control agent. Without wishing to be bound by any particular theory, it is postulated that the nicotine may be partially bound within an agar agar gel which may be formed during manufacture. This appears to provide both a highly stable nicotine composition, which despite the use of free base nicotine and high levels of moisture is able to maintain a long shelf life. Moreover, the nicotine release profile of the composition is fast and consistent, providing excellent product performance.
This performance is provided despite a relatively small quantity of agar agar being provided in the composition. The agar agar is preferably present in an amount from 0.1wt% to about 1.2 wt%. It is preferably present in a ratio of agar agar to nicotine of 0.1 : 1 to about 1.2: 1, preferably from about 0.1 : 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1. This is a significantly lower ratio than would be required for prior art stabilizing agents.
Any food or pharmaceutical grade agar agar may be utilized in the present invention. Specific examples include Rokoagar (RTM) RGM 600 and RGM 800, as supplied by Industries Roko, S.A..
In preferred embodiments, the composition may have a general composition as follows: a. From about 0.2wt% to about 3wt% nicotine in free base form; b. Microcrystalline cellulose, in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt% and preferably above 40 wt%; d. buffer salts ammonium chloride in an amount 0.05 wt% and lwt% and sodium bicarbonate in an amount from about 0.1 wt% to about 1 wt%; e. a release control agent comprising agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, such as a. flavourings in an amount from 0.5 wt% to about 3 wt%, b. flavour enhancers such as sodium chloride in an amount between 2wt% and 8wt%,
c. sweeteners such as xylitol in an amount from about between 1 wt% and 2 wt% and/or acesulfame K in an amount from 0.05 wt% to 1 wt%; and d. preservatives, such as potassium sorbate in an amount from about 0.25 wt% to about 1 wt%. e. tobacco in a quantity from 0 wt% to 3 wt%.
In a further embodiment, there is provided a process for the manufacture of tobacco -free or low-tobacco nicotine compositions. The process involves the mixing in a vessel (such as an autoclave) the native cellulose in a portion of from 30 wt% to 60 wt% of the intended final composition and agar agar in a portion of from 0.1 wt% to 2 wt% of the final composition, each in powder or granular form. One or more of the other solid components of the composition, such as pH control salts, flavour enhancers, sweeteners or preservatives may also be added at this stage of the process, though any tobacco intended for inclusion in the final composition should ideally be held until the remainder of the composition is complete.
At least a portion of the water (preferably at least 10wt% of the intended final composition) is then added to the composition and the composition is heated. The heating may take place in a number of ways. The mixing vessel may be heated, for example by use of a heating manifold. Alternatively or additionally, the water may be heated prior to its introduction to the mixing vessel or some or all of the water may be added as steam.
The temperature of the resulting precursor mixture should be at least 50°C, preferably at least 60°C and more preferably at least 70°C. The precursor is heated such that the agar agar at least partially dissolves in the water. Without wishing to be bound by any theory, it is postulated that the low concentration of agar agar coupled with shear applied during mixing, sufficient dissolution of agar agar may be obtained at such temperatures.
While the heated precursor mixture is being mixed, the nicotine is added to the precursor in an amount from 0.2 wt% to 2 wt% of the final composition. At this stage, other liquid components of the composition, such as flavourings, may be added.
Optionally, a second portion of water (preferably at least 10wt% of the intended final composition) is then added to the composition and the composition is heated, again to at least 50°C, preferably at least 60°C and more preferably at least 70°C.
The precursor is then allowed to cool, preferably while mixing is continued. The resulting composition may be set aside. Without wishing to be bound by any particular theory, it is believed that the agar agar forms a gel which at least partially encapsulates the nicotine which is present, stabilizing it and also providing excellent release properties.
In an optional finishing step, the resulting composition may have further water added to it, preferably with the water at ambient temperature. This step is to afford a greater content to the composition where required. In some embodiments, flavour enhancers, sweeteners or preservatives may be added at this stage, additionally to or in the alternative to their addition earlier in the process.
The finished composition may optionally be mixed with tobacco in an amount of up to 5 wt% of the final composition. The composition is soft to the touch, produces little dust and does not form clumps. The product is white in colour. In preferred embodiments, it is packed into saliva permeable pouches ready for oral delivery.
Examples
A number of compositions were produced according to the method described above.
0.7g portions of each of the finished compositions were packed into a saliva permeable pouch and tested according to the following release test:
A single person avoids nicotine intake for 10 hours before the experiment starts and avoids food or drink intake 1 hour before the experiment starts. Prior to the procedure, the testing person rinses his or her mouth with water and waits for 10 minutes.
A pouch is taken and the weight is measured before being placed under the lip of the testing person. The pouch is kept in place, without moving, for 5 minutes. The pouch is then removed and placed in a 50cm3 distilled water and stirred or shaken for 30 minutes. A sample is taken and analysed for its nicotine content using HPLC.
The tester then waits at least one hour before repeating the experiment, holding the pouch in place for 10, 20, 30 and 40 minutes on successive repeats.
The results of the release tests are plotted in Figure 1. As can be seen, a slight increase in the release rate and total release of nicotine over 40 minutes can be seen with the inclusion of 20 wt% agar agar. However, as can be surprisingly seen, a relatively small proportion of agar agar in the composition (0.3 wt%, with 0.6 wt% nicotine) provides a very significant increase in both release rate and total release over 40 minutes.
Further compositions, identical to those of Example 1 but which comprised different stabilizers in place of agar agar were prepared and tested according to the same method. The stabilizers used in these examples are shown in the table below:
The results of the release tests are plotted in the graph at Figure 2, with the plot of Example 1 overlaid. It is clear from the plot that agar agar provides for the greatest overall release of nicotine over a 40 minute period and also provides for a significantly
faster release over the first 10 minutes of use. This provides significant advantages for users seeking to cease smoking. pH Test - Corresta Method No. 69, 2017
A pH electrode is calibrated using at least two pH buffers (4,00 and 7,00 or 7,00 and 10,00) to produce a two-point calibration that will cover the pH range of the products tested. Calibration is performed in conjunction with the measurements of the samples and at 23°C. The calibration slope must be within 95 % - 105 % before the electrode can be used for sample measurements. The electrode must be rinsed, before and after each measurement, with water.
The samples for testing are allowed to reach room temperature before preparation. Samples are then mixed with water at a concentration of 5 wt% and shaken or stirred for 30 minutes. The pH electrode is then used to determine the pH of the water in the sample mixture.
Comparative Examples 10 to 12
Comparative examples 10-12 list commercial products which are based on a nicotine salt and featuring low moisture content, i.e., below 10% wt. These products generally feature long shelf life of at least 12 months. However, miscoloration and lumpiness increase with increasing moisture content. Very dry products may dust during storage and be difficult to handle during packaging. Low moisture products typically feature poor palatability (dry mouthfeel) and show delayed nicotine release. The appearance of samples is presented in Figure 3.
Comparative Examples 13 to 17
Comparative examples 13-17 list commercial products based on a nicotine free-base and featuring high moisture content, i.e., above 40% wt. Lumpiness and various degrees of miscoloration are characteristic to nearly all products. Comparative Examples 13 to 16 are variations of the same product from the same manufacturer, that vary mainly with respect to aromas, release modifiers, and sweeteners used. The products in these examples contain calcium chloride. Typically, calcium chloride is used as excipient with water binding properties and as antimicrobial preservative. The appearance of samples is presented in Figure 3.
Comparative Example 13
Comparative Examples 18 and 19
Comparative examples 18 and 19 list commercial products based on free-base nicotine and featuring medium moisture content, i.e., below 10-30% wt. These products feature a shelf life of around 6-12 months. Both products exhibit signs of miscoloration and lumpiness. Comparative Example 16, rich in sugar alcohol, is especially prone to form lumps, which harden over time, thereby significantly decreasing product palatability. The appearance of samples is presented in Figure 3.
EXAMPLE 2 Example 2 represent an example of formulation according to the present invention. The product features high moisture content and high nicotine stability during at least 12 months of storage. No signs of miscoloration, lumping or dusting are observed after storage.
Example 2
The Examples show that compositions of the present invention provide a soft, white product that avoids clumping and is thus palatable to use and easy to pack and manufacture. It also has a substantial shelf life and delivers nicotine quickly and consistently to the user.
The invention is as defined in the following claims.
Claims
Claims l.A composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar and/or derivatives of agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.
2. A composition according to claim 1, further comprising additional ingredients, preferably in an amount from about 1 wt% to about 10 wt% or more preferably in an amount from about 1 wt% to about 8 wt%.
3. A composition according to claim 1 or claim 2 wherein the additional ingredients comprise one or more additives selected from flavourings, flavour enhancers, sweeteners and preservatives.
4. A composition according to claims 2 or 3 wherein the additional ingredients comprise sweeteners, preferably in an amount from about lwt% to about 3 wt %.
5. A composition according to claim 4, wherein the sweeteners comprise compounds selected from sugars (such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose), sugar alcohols (such as xylitol, maltitol, sorbitol, erythritol) and/or sugar substitutes (such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides).
6. A composition according to claim 4 or claim 5 comprising a sugar alcohol in an amount less than 3 wt%, preferably less than 2 wt%, such as between 1 wt% and 2 wt%.
7. A composition according to any of claims 4 to 6 comprising a sugar substitute in an amount less than 1 wt%, preferably less than 0.5 wt%, such as between 0.05 wt% and 0.3 wt%.
8. A composition according to claim 6 or claim 7 wherein the or a sugar alcohol comprises xylitol and/or the or a sugar substitute comprises acesulfame K.
9. A composition according to any of claims 2 to 8 further comprising one or more preservatives selected from calcium chloride, salts of sorbic acid (such as potassium sorbate), salts of benzoic acid (such as sodium benzoate), nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts.
10. A composition according to claim 9, wherein potassium sorbate is present in an amount less than about lwt%, preferably between 0.1wt% and 0.5wt%, such as between about 0.25wt% and about 0.35wt%.
11. A composition according to any of claims 1 to 9, wherein the pH control salts comprise buffering salts such as a combination of ammonium chloride and sodium bicarbonate.
12. A composition according to claim 11, where ammonium chloride is present in an amount between 0.05 wt% and lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.15 wt% and 0.25 wt%.
13. A composition according to any preceding claim, where sodium bicarbonate is present in an amount between less than lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.2 wt% and 0.3 wt%.
14. A composition according to any preceding claim comprising greater than 40wt% water, for example between 40 wt% and 50 wt% water, preferably between about 44 wt% and about 48 wt% water.
15. A composition according to any preceding claim wherein the filler material comprises powdered cellulose and/or microcrystalline cellulose (MCC).
16. A composition according to any preceding claim, wherein the release control agent comprises agar agar in an amount less than about lwt%, preferably less than 0.7wt%.
17. A composition according to claim 16, wherein the release control agent comprises agar agar in an amount from about 0.2 wt% to about 0.7wt%, preferably in an amount from about 0.2wt% to about 0.5wt%.
18. A composition according to any preceding claim, wherein the ratio of agar agar to nicotine is less than about 1.3: 1.
19. A composition according to any preceding claim, wherein the ratio of agar agar to nicotine is from about 0.1: 1 to about 1.2: 1, preferably from about 0.1 : 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1.
20. A composition according to any preceding claims further comprising tobacco leaf in an amount less than 5 wt%, preferably about 1 wt% to 3 wt%.
21. A composition according to any preceding claim where the pH as measured by
Coresta Method No.69, 2017, is from 6 to 9, preferably from 7 to 9 and more preferably from 7 to 8.5.
22. A composition according to any of claims 3 to 21 wherein the flavour enhancers are selected from the group comprising sodium chloride, glutamate salts, glycine salts, inosinic acid salts and 5'-ribonucleotide salts.
23. A composition according to claim 22 comprising sodium chloride in an amount less than 8 wt%, preferably between 1 wt% and 7 wt%.
24. A composition according to any of claims 3 to 23 comprising flavouring compounds in an amount less than about 5 wt% of the total composition, for example less than 3 wt% of the composition or between 0.5 wt% and 3 wt% of the composition.
25. A composition according to any preceding claim, wherein the the quantity of nicotine is between 0.2wt% and 3 wt%, or between 0.2wt% and 2wt%.
26. A composition according to any preceding claim consisting essentially of the claimed components.
27. A water or saliva permeable pouch containing a composition according to any preceding claim.
28. A package containing a plurality of pouches according to claim 27.
29. A process for forming a nicotine containing composition according to any of claims 1 to 26 comprising: a. combining in a mixer native cellulose material in an amount 40 wt% to 60 wt% of the intended composition with agar agar (and/or derivatives of agar agar)powder in an amount 0.2 wt% to 2 wt% of the intended composition, thereby to form a precursor composition; b. adding water to the precursor composition and mixing at a temperature greater than 50°C; c. adding to the precursor composition nicotine in free base form, in an amount 0.2wt% to about 2wt% of the intended final composition, while the temperature is greater than 50°C; d. allowing the mixture to cool.
30. A process according to claim 29, wherein additional water is added between steps
(c) and (d).
31. A process according to claim 29 or 30, wherein in steps (b) and (c), the mixing of the precursor is at a temperature greater than about 60°C, preferably above about 70°C, preferably above 80°C.
32. A process according to any of claims 29 to 31, wherein in step (b) the water is provided to the precursor at a temperature above about 70°C, preferably above about 80°C.
33. A process according to claim 32, wherein in step (b) the water is provided to the precursor is in the form of steam or vapour.
34. A process according to any of claims 30 to 33, wherein additional water added between steps (c) and (d) is at a temperature greater than about 70°C, preferably above about 80°C.
35. A process according to any of claims 34, wherein additional water added between steps (c) and (d) is in the form of steam or vapour.
process according to any of claims 29 to 35, wherein the precursor mixture is heated while in the mixer, for example during step (b) and/or (c) and or during or after any addition of water following step (c). process according to any of claims 29 to 36, wherein further water is added to the composition after step (d). process according to any of claims 29 to 37, wherein any of the following components are added to the precursor mixture prior to step (b): a. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt% of the intended composition; b. additional ingredients, preferably in an amount up to about 12 wt% of the intended composition. process according to any of claims 29 to 38 where the intended composition is a composition according to any of claim 1 to 26. se as a nicotine release control agent of agar agar in a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar and/or derivatives of agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%.se as a nicotine stabilising agent of agar agar in a composition comprising: a. From about 0.2wt% to about 5wt% nicotine in free base form; b. a native cellulose material in an amount from about 35 wt% to about 60 wt%; c. water in an amount at least 35 wt%; d. one or more pH control salts in an amount from about 0.5 wt% to about 3 wt%; e. a release control agent comprising agar agar and/or derivatives of agar agar in an amount from about 0.1wt% to about 2 wt% f. optional additional ingredients, preferably in an amount up to about 12 wt%. use according to claim 38 or claim 39, wherein the composition further comprises additional ingredients, preferably in an amount from about 1 wt% to about 10 wt% or more preferably in an amount from about 1 wt% to about 8 wt%.
43. A use according to claims 40 to 42 wherein the additional ingredients in the composition comprise one or more additives selected from flavourings, flavour enhancers, sweeteners and preservatives.
44. A use according to claims 42 or 43 wherein the additional ingredients comprise sweeteners, preferably in an amount from about lwt% to about 3 wt %.
45. A use according to claim 44, wherein the sweeteners comprise compounds selected from sugars (such as sucrose, fructose, glucose, dextrose, maltose, lactose, galactose), sugar alcohols (such as xylitol, maltitol, sorbitol, erythritol) and/or sugar substitutes (such as aspartame, saccharin, sucralose, allulose, acesulfame K, cyclamate or steviol glycosides).
46. A use according to claim 44 or claim 45 comprising a sugar alcohol in an amount less than 3 wt%, preferably less than 2 wt%, such as between 1 wt% and 2 wt%.
47. A composition according to any of claims 46 comprising a sugar substitute in an amount less than 1 wt%, preferably less than 0.5 wt%, such as between 0.05 wt% and 0.3 wt%.
48. A according to claim 46 or claim 47 wherein the or a sugar alcohol comprises xylitol and/or the or a sugar substitute comprises acesulfame K.
49. A use according to any of claims 42 to 48 further comprising one or more preservatives selected from calcium chloride, salts of sorbic acid (such as potassium sorbate), salts of benzoic acid (such as sodium benzoate), nitrate salts, nitrite salts, sulfate salts, sulfite salts and proponiate salts.
50. A use according to claim 49, wherein potassium sorbate is present in an amount less than about lwt%, preferably between 0.1wt% and 0.5wt%, such as between about 0.25wt% and about 0.35wt%.
51. A use according to any of claims 40 to 49, wherein the pH control salts comprise buffering salts such as a combination of ammonium chloride and sodium bicarbonate.
52. A use according to claim 51, where ammonium chloride is present in an amount between 0.05 wt% and lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.15 wt% and 0.25 wt%.
53. A use according to any of claims 40 to 52, where sodium bicarbonate is present in an amount between less than lwt%, preferably between 0.1wt% and 0.5 wt%, for example between 0.2 wt% and 0.3 wt%.
54. A use according to any of claims 40 to 53, comprising greater than 40wt% water, for example between 40 wt% and 50 wt% water, preferably between about 44 wt% and about 48 wt% water.
55. A use according to any of claims 40 to 54 wherein the filler material comprises powdered cellulose and/or microcrystalline cellulose (MCC).
56. A use according to any of claims 40 to 55, wherein the release control agent comprises agar agar in an amount less than about lwt%, preferably less than 0.7wt%.
57. A use according to claim 56, wherein the release control agent comprises agar agar in an amount from about 0.2 wt% to about 0.7wt%, preferably in an amount from about 0.2wt% to about 0.5wt%.
58. A use according to any of claims 40 to 57, wherein the ratio of agar agar to nicotine is less than about 1.3: 1.
59. A use according to any of claims 40 to 58, wherein the ratio of agar agar to nicotine is from about 0.1: 1 to about 1.2: 1, preferably from about 0.1: 1 to about 1: 1, more preferably from about 0.1 : 1 to about 0.8: 1.
60. A use according to any of claims 40 to 59 further comprising tobacco leaf in an amount less than 5 wt%, preferably about 1 wt% to 3 wt%.
61. A use according to any of claims 40 to 60 where the pH as measured by Coresta
Method No.69, 2017, is from 6 to 9, preferably from 7 to 9 and more preferably from 7 to 8.5.
62. A use according to any of claims 43 to 61 wherein the flavour enhancers are selected from the group comprising sodium chloride, glutamate salts, glycine salts, inosinic acid salts and 5'-ribonucleotide salts.
63. A use according to claim 62 comprising sodium chloride in an amount less than 8 wt%, preferably between 1 wt% and 7 wt%.
64. A use according to any of claims 43 to 63 comprising flavouring compounds in an amount less than about 5 wt% of the total composition, for example less than 3 wt% of the composition or between 0.5 wt% and 3 wt% of the composition.
65. A use according to any of claims 40 to 64, wherein the quantity of nicotine is between
0.2wt% and 3 wt%, or between 0.2wt% and 2wt%
66. A use according to any of claims 40 to 65, wherein the composition consists essentially of the claimed components.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/056762 WO2023174523A1 (en) | 2022-03-15 | 2022-03-15 | Nicotine composition |
EP22715985.2A EP4322772A1 (en) | 2022-03-15 | 2022-03-15 | Nicotine composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/056762 WO2023174523A1 (en) | 2022-03-15 | 2022-03-15 | Nicotine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023174523A1 true WO2023174523A1 (en) | 2023-09-21 |
Family
ID=81306767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/056762 WO2023174523A1 (en) | 2022-03-15 | 2022-03-15 | Nicotine composition |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4322772A1 (en) |
WO (1) | WO2023174523A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010104464A1 (en) | 2009-03-13 | 2010-09-16 | Excellens Tech. Products Aps | Oral delivery product |
WO2010114445A1 (en) | 2009-04-03 | 2010-10-07 | X-International Aps | Plant fiber product and method for its manufacture |
US8469036B2 (en) * | 2003-11-07 | 2013-06-25 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
EP1998748B1 (en) * | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
WO2020207735A1 (en) * | 2019-04-08 | 2020-10-15 | Philip Morris Products S.A. | Aerosol-generating film |
WO2020245431A1 (en) * | 2019-06-05 | 2020-12-10 | Philip Morris Products S.A. | Nicotine composition, method for making and aerosol generating articles comprising such |
WO2020244721A1 (en) | 2019-06-07 | 2020-12-10 | Ncp Nextgen A/S | Nicotine pouch composition and pouch comprising such |
-
2022
- 2022-03-15 EP EP22715985.2A patent/EP4322772A1/en active Pending
- 2022-03-15 WO PCT/EP2022/056762 patent/WO2023174523A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8469036B2 (en) * | 2003-11-07 | 2013-06-25 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
EP1998748B1 (en) * | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
WO2010104464A1 (en) | 2009-03-13 | 2010-09-16 | Excellens Tech. Products Aps | Oral delivery product |
WO2010114445A1 (en) | 2009-04-03 | 2010-10-07 | X-International Aps | Plant fiber product and method for its manufacture |
WO2020207735A1 (en) * | 2019-04-08 | 2020-10-15 | Philip Morris Products S.A. | Aerosol-generating film |
WO2020245431A1 (en) * | 2019-06-05 | 2020-12-10 | Philip Morris Products S.A. | Nicotine composition, method for making and aerosol generating articles comprising such |
WO2020244721A1 (en) | 2019-06-07 | 2020-12-10 | Ncp Nextgen A/S | Nicotine pouch composition and pouch comprising such |
US20200383373A1 (en) * | 2019-06-07 | 2020-12-10 | Fertin Pharma A/S | Nicotine pouch product |
US20200383372A1 (en) | 2019-06-07 | 2020-12-10 | Fertin Pharma A/S | Nicotine pouch composition and pouch comprising such |
Non-Patent Citations (2)
Title |
---|
CONAGHEY O M ET AL: "THE RELEASE OF NICOTINE FROM A HYDROGEL CONTAINING ION EXCHANGE RESINS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 170, no. 2, 15 August 1998 (1998-08-15), pages 215 - 224, XP008043002, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(98)00144-6 * |
STANFIL ET AL., NICOTINE & TOBACCO RESEARCH, 2021, pages 1590 - 1596 |
Also Published As
Publication number | Publication date |
---|---|
EP4322772A1 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6047697B2 (en) | Pouch containing nicotine in free salt form | |
KR101831463B1 (en) | Inhibition of sensory irritation during consumption of non-smokeable tobacco products | |
JP2022535586A (en) | nicotine pouch composition | |
EP2830622B1 (en) | A nicotine oral delivery product containing a powder enclosed in a water insoluble pouch, wherein said powder comprises nicotine and a chewing gum composition | |
JP2012522765A (en) | Plant fiber product and method for producing the same | |
JPH05504949A (en) | smoking substitute | |
US20110232662A1 (en) | Gel-coated novel portion snus | |
EP4146279A1 (en) | New compositions for oral or nasal use | |
JP2022548626A (en) | nicotine pouch | |
JP2023520044A (en) | Novel compositions for oral or nasal use | |
EP3868222A1 (en) | Smokeless article | |
EP4106556A1 (en) | Smokeless article | |
WO2023174523A1 (en) | Nicotine composition | |
EP3868223A1 (en) | Smokeless article | |
EP3868224A1 (en) | Smokeless article | |
JP2023523960A (en) | nicotine oral delivery products | |
JP6001108B2 (en) | Plant fiber product and method for producing the same | |
CA3196911C (en) | Compositions and methods for sublingual delivery of nicotine | |
WO2023067675A1 (en) | Oral composition containing trehalose | |
EP4232006A1 (en) | A new powder composition | |
WO2023143689A1 (en) | Method for producing a pouch composition | |
JP2024513106A (en) | Nicotine products in flavored oral pouches containing acids | |
WO2023143690A1 (en) | Pouch composition comprising one or more water insoluble fibers | |
WO2023112150A1 (en) | Oral product containing low molecular weight alginic acid compound and composition for said product | |
WO2023143687A1 (en) | Pouch composition with specific nicotine to solvent ratio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22715985 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022715985 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022715985 Country of ref document: EP Effective date: 20231116 |